Targeting GPD1 (such as small molecule inhibitors) may provide a new strategy for the comorbidity of NAFLD and CAD by reshaping macrophage function and improving metabolic abnormalities and inflammation. This evidence concerns the gene GPD1 and metabolic dysfunction-associated steatotic liver disease.